Private equity firm Fraziere Healthcare Partners has an eye for finding the angle in any investment market. Specializing in shareholder liquidity, incubation and growth equity financing, the company has a way with finding the sure bet in an otherwise highly-speculative industry.
In 2003, the firm saw potential for providing healthcare to prison inmates after cash-strapped governments began outsourcing these services to save money. Incarcerated individuals are amongst the few who have the constitutional right to medical care and with soaring prison populations, these people represented a very lucrative opportunity for private equity firms like Fraziere. But they haven’t stopped there.
The company was founded in 1991 by Allan D. Fraizer and he has led the firm as Managing Partner and Chairman for twenty-eight years. They have successfully raised eleven institutional funds and currently manage almost $4.2 billion in assets. Frazier Healthcare Partners takes an active role with helping their portfolio companies grow, drawing from the leadership team’s deep industry expertise and wide-spread network to help these businesses reach their full potential.
Most recently, the company helped Imago BioSciences raise $40 million in Series B financing. As a clinical stage, venture-funded pharmaceutical company, they specialize in improving the management of proliferative diseases such as acute myeloid leukemia. The contributed capital will be put towards advancing research and clinical development of treatments for myelofibrosis and other myeloid neoplasms.
“Imago BioSciences is extremely gratified with the interest and support of the investment community; we are particularly pleased with the composition of this new investment syndicate,” said Hugh Young Rienhoff, CEO at Imago BioSciences. “These funds will enable Imago to advance our programs through the completion of Phase 2b studies.”
Frazier operates a Growth Venture arm that focuses on investment opportunities predominantly in healthcare and pharmaceutical services, medical products and related sectors. They also operate a Life Sciences arm that invests in therapeutics and other sectors that address unmet medical needs. The firm typically invests between $3 million to $100 million per transaction and maintains assets in Canada, Europe and the United States.
Of their investment in Imago, the firm feel positive about the company’s potential. “Frazier, along with the full support of the Series A syndicate, were enthusiastic about this financing. We view the program to treat myeloproliferative diseases as extremely promising,” said Patrick Heron of Frazier Healthcare Partners.
